Delving into the Latest Updates on Glycovax Pharma, Inc. with Synapse

概览

疾病领域	数量

感染	1

排名前五的药物类型	数量

疫苗	2

关联

2

项与 Glycovax Pharma, Inc. 相关的药物

Glycovax-002

靶点-

作用机制

免疫刺激剂

在研机构

Seppic S.A. [+3]

原研机构

Glycovax Pharma, Inc.初创企业

在研适应症-

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

Semi-synthetic COVID-19 vaccine (Glycovax Pharma)

靶点-

作用机制

免疫刺激剂

在研机构

Glycovax Pharma, Inc.初创企业

原研机构

Glycovax Pharma, Inc.初创企业

在研适应症

新型冠状病毒感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

1

项与 Glycovax Pharma, Inc. 相关的临床试验

NCT05799651 / Active, not recruiting临床1期

A Randomised, Double-Blind, Dose-Escalation Phase I Study in Healthy Adults to Assess the Safety, Tolerability and Immunogenicity of Glycovax-002, a Novel Vaccine Candidate Against COVID-19

Glycovax Pharma has developed a glycoconjugate vaccine candidate called Glycovax-002 to fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the origin of COVID-19.
The aim of the study is to assess the safety, reactogenicity and immunogenicity of Glycovax-002 in humans. The study is a phase I, placebo-controlled, dose-escalation study conducted in 36 healthy females and males aged between 18 and 55 years old. The vaccine will be administered three times with a two-week time interval between each dose.
Dose escalation is conducted in three steps. At each step, 9 participants receiving the vaccine will be randomized with 3 participants receiving placebo (normal saline). Progression to next step is conditional to a DSMB's approval.

开始日期2023-04-28

申办/合作机构

Glycovax Pharma, Inc.初创企业

[+4]

100 项与 Glycovax Pharma, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Glycovax Pharma, Inc. 相关的专利（医药）

登录后查看更多信息

2

项与 Glycovax Pharma, Inc. 相关的文献（医药）

2019-05-01·Drug Discovery Today2区 · 医学

Exploration of biomedical dendrimer space based on in-vivo physicochemical parameters: Key factor analysis (Part 2)

2区 · 医学

Review

作者: Majoral, Jean-Pierre ; Mignani, Serge ; Roy, René ; Ceña, Valentin ; Shi, Xiangyang ; Rodrigues, João ; El Kazzouli, Saïd

In nanomedicine, the widespread concern of nanoparticles in general, and dendrimers, in particular, is the analysis of key in-vivo physicochemical parameters to ensure the preclinical and clinical development of 'safe' bioactive nanomaterials. It is clear that for biomedical applications, biocompatible dendrimers, used as nanocarriers or active per se, should be devoid of toxicity and immunogenicity, and have adequate PK/PD behaviors (adequate exposure) in order to diffuse in different tissues. Functionalization of dendrimers has a dramatic effect on in-vivo physicochemical parameters. In this review, we highlighted key in-vivo physicochemical properties, based on data from biochemical, cellular and animal models, to provide biocompatible dendrimers. Up-to-date, only scarce studies have been described on this topic.

2018-04-01·Translational Oncology3区 · 医学

Preclinical Analysis of JAA-F11, a Specific Anti–Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging

3区 · 医学

ArticleOA

作者: Roy, Rene ; Fisk, John C ; Sajjad, Munawwar ; Karacosta, Loukia G ; Turner, Bradley ; Koury, Steven ; Jessee, Joseph ; Tati, Swetha ; Adams, Julia ; Johnson, Holly ; Rittenhouse-Olson, Kate ; Ghazal, Diala ; Olson, James R ; Ludwig, Rachel

The tumor specificity of JAA-F11, a novel monoclonal antibody specific for the Thomsen-Friedenreich cancer antigen (TF-Ag-alpha linked), has been comprehensively studied by in vitro immunohistochemical (IHC) staining of human tumor and normal tissue microarrays and in vivo biodistribution and imaging by micro-positron emission tomography imaging in breast and lung tumor models in mice. The IHC analysis detailed herein is the comprehensive biological analysis of the tumor specificity of JAA-F11 antibody performed as JAA-F11 is progressing towards preclinical safety testing and clinical trials. Wide tumor reactivity of JAA-F11, relative to the matched mouse IgG₃ (control), was observed in 85% of 1269 cases of breast, lung, prostate, colon, bladder, and ovarian cancer. Staining on tissues from breast cancer cases was similar regardless of hormonal or Her2 status, and this is particularly important in finding a target on the currently untargetable triple-negative breast cancer subtype. Humanization of JAA-F11 was recently carried out as explained in a companion paper "Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis" (Neoplasia 19: 716-733, 2017), and it was confirmed that humanization did not affect chemical specificity. IHC studies with humanized JAA-F11 showed similar binding to human breast tumor tissues. In vivo imaging and biodistribution studies in a mouse syngeneic breast cancer model and in a mouse-human xenograft lung cancer model with humanized ¹²⁴I- JAA-F11 construct confirmed in vitro tumor reactivity and specificity. In conclusion, the tumor reactivity of JAA-F11 supports the continued development of JAA-F11 as a targeted cancer therapeutic for multiple cancers, including those with unmet need.

100 项与 Glycovax Pharma, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Glycovax Pharma, Inc. 相关的转化医学

登录后查看更多信息